Nephropathy - Pipeline Review, H2 2015 Is Released Nephropathy - Pipeline Review, H2 2015 Summary Global Markets Direct s, Nephropathy - Pipeline Review, H2 2015, provides an overview of the Nephropathys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Nephropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
1
with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=173385/nephropathy-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173385/nephropathy-pipeline-review-h2-2015 Table of Contents
Introduction 5 Global Markets Direct Report Coverage 5 Nephropathy Overview 6 Therapeutics Development 7 Pipeline Products for Nephropathy - Overview 7 Nephropathy - Therapeutics under Development by Companies 8 Nephropathy - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Nephropathy - Products under Development by Companies 12 Nephropathy - Companies Involved in Therapeutics Development 13 Anthera PharmaceuticalsInc. 13 Boehringer Ingelheim GmbH 14 ChemoCentryx, Inc. 15 Complexa, Inc. 16 Promedior, Inc. 17 Nephropathy - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 2
Assessment by Molecule Type 25 Drug Profiles 27 blisibimod - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 CCX-168 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CXA-10 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 imatinib mesylate - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 PRM-151 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 R-801 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36
3
R-901 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Nephropathy - Recent Pipeline Updates 42 Nephropathy - Dormant Projects 52 Nephropathy - Discontinued Products 53 Nephropathy - Product Development Milestones 54 Featured News & Press Releases 54 Mar 16, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy 54 Oct 01, 2014: Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions For Blisibimod 54 Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 54 Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With Blisibimod 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 4
Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
Read More http://www.idatainsights.com/reports-landing-page.php?id=173385/nephropathypipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
5
6